Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Revenue of Xeris Biopharma Holdings, Inc. (XERS)
Revenue in 2024 (TTM): $163.91 M
According to Xeris Biopharma Holdings, Inc.'s latest financial reports the company's current revenue (TTM) is $163.91 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Xeris Biopharma Holdings, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2024 | $163.91 M | $135.27 M | $-23,735,000 | $-63,504,000 | $-62,255,000 |
| 2023 | $110.25 M | $87.61 M | $-69,314,000 | $-96,084,000 | $-94,660,000 |
| 2022 | $110.25 M | $87.61 M | $-113,666,000 | $-96,084,000 | $-94,660,000 |
| 2021 | $49.59 M | $36.27 M | $-80,079,000 | $-122,725,000 | $-122,725,000 |
| 2020 | $20.16 M | $10.83 M | $-117,797,000 | $-91,250,000 | $-91,140,000 |
| 2019 | $2.47 M | $2.42 M | $-57,215,000 | $-60,080,000 | $-60,080,000 |
| 2018 | $1.56 M | $1.55 M | $-26,377,000 | $-26,554,000 | $-26,554,000 |
| 2017 | $1.08 M | $1.07 M | $-13,091,000 | $-13,209,000 | $-13,209,000 |